Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Chloramphenicol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Dose The recommended dose is 1 to 2 drops to each infected eye up to six times a day. You should continue your treatment for 2 days after symptoms disappear, to prevent the recurrence of infection. The maximum recommended duration of treatment is 14 days. If your eyes get worse or are not better after a few days of using these eye drops, see your doctor or eye specialist or pharmacist. Use in children It may be necessary to adjust the dose for newborn infants as, due to their immature metabolism they may be at risk of dose-related adverse effects. The maximum duration of treatment is 10-14 days. Do not allow the tip of the multi-dose container to touch the eye or areas around the eye. It could cause injury to your eye. The eye drops solution may become contaminated with bacteria that can cause eye infections leading to serious damage of the eye, even loss of vision. To avoid possible contamination of the multi-dose container, keep the tip of the multi-dose container away from contact with any surface. Instructions for use Before instillation of the eye drops: -W ash your hands before opening the bottle. -D o not use this medicine if you notice that the tamper-proof seal on the bottle neck is broken before you first use it. -W hen using for the first time, before delivering a drop to the eye, you should first of all practice using the dropper bottle by squeezing it slowly to deliver one drop into the air, away from the eye. -W hen you are confident that you can deliver one drop at a time, choose the position that you find most comfortable for the instillation of the drops (you can sit down, lie on your back, or stand in front of a mirror). Instillation: 1. H old the bottle directly below the cap and turn the cap to open the bottle. Do not touch anything with the tip of the bottle to avoid contamination of the solution.
2. T ilt your head backwards and hold the bottle above your eye. 3. P ull the lower eyelid down and look up. Squeeze the bottle gently in the middle and let a drop fall into your eye. Please note that there might be a few seconds delay between squeezing and the drop coming out. Do not squeeze too hard. If you are not sure how to administer your medicine, ask your doctor, pharmacist or nurse.
Eykappo contains a medicine called chloramphenicol. This belongs to a group of medicines called antibiotics. It is used to treat infections of your eyes. Sometimes parts of the outer surface of the eye, such as the cornea (the transparent membrane covering the surface of the eye) or the conjunctiva (the lining of the inside of the eyelids and part of the eye), may become infected with bacteria. These eye drops can be used to treat this infection and are effective against 4. B link a few times so that the drop many different types of bacteria. spreads over the eye. If the eye infection is very severe, your doctor may give you antibiotic tablets as well as these antibiotic eye drops. This medicine is indicated for children, adults and the elderly. Eykappo eye drops solution is a sterile solution that does not contain 5. A fter using Eykappo, press a finger a preservative. into the corner of your eye, by the nose for 2 minutes. This helps to stop the solution getting into the 2. What you need to know rest of your body. before you use Eykappo Do not use Eykappo:
Eykappo
6. R epeat the instructions 2 – 5 to deliver a drop into the other eye also, if your doctor has instructed you to do this. Sometimes only one eye needs to be treated and your doctor will advise if this applies to you and which eye needs treatment. 7. A fter each use and prior to recapping, the bottle should be shaken once in a downwards direction, without touching the dropper tip, in order to remove any residual liquid on the tip. This is necessary in order to ensure delivery of subsequent drops.
8. A fter you have used all doses there will be some Eykappo left in the bottle. You should not be concerned since an extra amount of Eykappo has been added and you will get the full amount of Eykappo that your doctor has prescribed. Do not attempt to use the excess medicine remaining in the bottle after you have completed the course of treatment. Do not use the eye drops for longer than 28 days after first opening the bottle. If you use more Eykappo than you should An overdose is very unlikely to occur. If you suddenly feel unwell after receiving the drops, tell your doctor or eye specialist or contact your nearest emergency department immediately. If you forget to use Eykappo If you forget a dose, use your drops as soon as you remember and then go on as before. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
23346700
Like all medicines, this medicine can cause side effects, although not everybody gets them. •E ykappo may cause burning, stinging, itching and skin irritation (including dermatitis) around the area it has been used on. These effects are not permanent. •S welling of your face, lips, tongue and/or throat which may cause difficulty breathing and/or swallowing (angioedema) may occur. If this happens, get medical help straight away. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme (website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store). By reporting side effects you can help provide more information on the safety of this medicine.
Eykappo
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and on the carton after 'EXP'. The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Do not freeze. Store in the original package in order to protect from light. After first opening, the product may be stored for a maximum of 28 days. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Eykappo contains •T he active ingredient is chloramphenicol. Each multi-dose container contains approximately 10ml eye drops solution of chloramphenicol 5mg/ml. •T he other ingredients are borax, boric acid, sodium hydroxide or/and hydrochloric acid (for pH adjustment) and water for injections. What Eykappo looks like and contents of the pack 10ml of Eykappo eye drops solution is filled in a white opaque 11ml LDPE bottle and white Novelia nozzle (HDPE and silicone) with a white HDPE cap. Each carton contains 1 multi-dose container.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder Aspire Pharma Ltd Unit 4, Rotherbrook Court Bedford Road Petersfield Hampshire GU32 3QG United Kingdom Manufacturer Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece and EXCELVISION 27 st. La Lombardière, Zl La Lombardière, ANNONAY 07100 France This leaflet was last revised in: 03/2022 1010375-P5.5
23346700
Eykappo (Chloramphenicol) 5mg/ml Eye Drops comes as eye drops containing 5mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Eykappo (Chloramphenicol) 5mg/ml Eye Drops is chloramphenicol.
Medicines with the same active substance, strength and form include: Mollifeye 5mg/ml Eye Drops, Solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Eykappo (Chloramphenicol) 5mg/ml Eye Drops, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Chloramphenicol is indicated in adults and children for the treatment of acute bacterial conjunctivitis.
Considerations should be given to official guidance on the appropriate use of antibacterial agents.
Posology
Adults (including the elderly) and children
One to two drops applied topically to each affected eye up to six times daily or more frequently if required. To decrease the risk for recurrent infection, treatment should continue for an additional 2 days after symptoms disappear. The maximum recommended treatment duration is 14 days.
Paediatric population
Dosage adjustment may be necessary in newborn infants because of reduced systemic elimination due to immature metabolism and the risk of dose-related adverse effects. The maximum duration of treatment is 10-14 days.
Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute following instillation of the drops.
Method of administration
For ocular use.
Eykappo eye drops solution is a sterile solution that does not contain a preservative.
Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures as this could cause injury to the eye.
Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In severe infections topical use of chloramphenicol should be supplemented with appropriate systemic treatment.
Prolonged use should be avoided as it may increase the likelihood of sensitisation and the emergence of resistant organisms.
Contact lenses should not be worn in an infected eye. Contact lenses should be removed during the period of treatment.
Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.)
Patients with a history of contact hypersensitivity to silver should not use this product as dispensed drops may contain traces of silver.
This medicinal product should not be given to a child younger than 2 years without medical advice, as it contains boron and may impair fertility in the future.
Since low systemic concentrations of chloramphenicol are expected after topical use, the risk for relevant interactions is expected to be low.
Pregnancy and breast-feeding
Safety for use in pregnancy and lactation has not been established, therefore, use only when considered essential by the physician. Chloramphenicol passes the placenta and is excreted in breast milk.
Fertility
No fertility data are available.
May cause transient blurring of vision on installation. Warn patients not to drive or operate hazardous machinery unless vision is clear.
Local
Sensitivity reactions such as transient irritation, burning, stinging, itching and dermatitis, may occur.
Systemic
Angioedema.
Paediatric population
The adverse reaction profile in children is expected to be similar to adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme (website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store).
Not applicable.
Ask anything about Eykappo (Chloramphenicol) 5mg/ml Eye Drops. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.